Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Our expertise across R&D, manufacture, and discovery of novel gene and cell therapies has us uniquely positioned to bring new medicines to patients in need.
Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.
Steven H. Rouhandeh
Mr. Rouhandeh has served as a Director of Abeona’s board since the Company’s public debut in 2015, and previously served as Executive Chairman of the Board of Directors from January 2015 to April 2020. He has been Chief Investment Officer of SCO Capital Partners, a group of New York based life sciences funds since 1997. Mr. Rouhandeh possesses a diverse background in financial services that includes experience in asset management, corporate finance, investment banking and law. He has been active throughout recent years as an executive in venture capital and as a founder of several companies in the biotech field. His experience also includes positions as Managing Director of a private equity group at Metzler Bank, a private European investment firm and Vice President, Investment Banking at Deutsche Bank. Mr. Rouhandeh was also a corporate attorney at New York City-based Cravath, Swaine & Moore. Mr. Rouhandeh holds a J.D., from Harvard Law School, Harvard University and B.A. Political Science, from Southern Illinois University.
Christine Silverstein brings over 15 years of experience in capital markets strategy, financial services, investor relations and healthcare media communications to the Company. Prior to her current role, she served as Chief Financial Officer for Abeona. Silverstein has held various executive roles within the biotechnology industry including Head of Investor Relations at Relmada Therapeutics, Inc., Vice President of Corporate Development at PlasmaTech Biopharmaceuticals, and Managing Director at SCO Financial Group, a life sciences fund. Earlier in her career, she held senior positions at leading New York corporate and capital market advisory firms. Silverstein began her career in financial services as an investment advisor at Royal Alliance Associates before moving to the investor and corporate relations industry. A member of the National Investor Relations Institute, Ms. Silverstein holds a B.S. from the Peter Tobin College of Business at St. John's University.
Todd Wider, M.D.
Todd Wider, M.D.became a director in May 2015 and serves as a member of the Audit Committee and Compensation Committee. Dr. Wider is a surgeon and has served as consultant to numerous entities in the biotechnology space. Dr. Wider holds an M.D. from Columbia College of Physicians and a B.A. from Princeton University.
Mr. Mann has over 20 years of experience in the financial and biotechnology industries. Most recently, he served as CFO at PolarityTE, Inc., a biotechnology and regenerative biomaterials company, where he was responsible for all financial operations. Prior to that, Mr. Mann was the Healthcare Portfolio Manager at Highbridge Capital Management and has held positions with Soros Fund Management, UBS Investment Group, Morgan Stanley and Deutsche Bank. Mr. Mann began his career as a scientist at Procter and Gamble and is named as an inventor on patents for skincare compounds and technologies. Mr. Mann has an MA (Cantab) and an MEng from Cambridge University where he studied Natural Sciences and Chemical Engineering.